Behavioral and psychological signs and symptoms of dementia: a practicing psychiatrist's viewpoint by E. Mintzer, Jacobo et al.
Alzheimer's disease typically presents with two often overlapping syndromes, one cognitive, the other behav-
ioral. The behavioral syndrome is characterized by psychosis, aggression, depression, anxiety, agitation, and other
common if less well-defined symptoms subsumed under the umbrella entity “behavioral and psychological
symptoms of dementia” (BPSD), itself divided into a number of subsyndromes: psychosis, circadian rhythm (sleep-
wake) disturbance, depression, anxiety, and agitation. It is BPSD with its impact on care providers that ultimately
precipitates the chain of events resulting in long-term institutional care. The treatment challenge involves
eliminating unmet medical needs (undiagnosed hip fracture and asymptomatic urinary tract infection or pneu-
monia). Pharmacologic intervention relies on risperidone and, increasingly, cholinesterase inhibitors for the con-
trol of psychosis (but with response rates of only 65% at tolerable doses), olanzapine and risperidone for anx-
iety, and carbamazepine and valproic acid for agitation. However, evidence increasingly favors
nonpharmacologic interventions, to the extent that these should now be considered as the foundation of BPSD
treatment. Problem behaviors are viewed as meaningful responses to unmet needs in the therapeutic milieu.
Because the progression and impact of BPSD varies between patients, interventions must be explored, designed,
implemented, and assessed on an individual basis. They include: family support and education, psychotherapy,
reality orientation, validation therapy, reminiscence and life review, behavioral interventions, therapeutic
activities and creative arts therapies, environmental considerations (including restraint-free facilities), behavioral
intensive care units, and workplace design and practices that aid the ongoing management of professional care-
giver stress. 
pproximately 10% of persons who reach the
age of 65 will develop Alzheimer’s disease (AD) or
another type of dementia.
1AD and other dementias usu-
ally present with two syndromes, a cognitive syndrome
and a behavioral syndrome,
2 which overlap (in most
patients) during the course of the disease.
3 The cogni-
tive syndrome is characterized by deficits in memory,
language,visual constructional abilities,and other areas
of intellectual functioning.
4The behavioral syndrome is
characterized by symptoms of psychosis, aggression,
depression, anxiety, agitation, and other common, but
less well-defined,behavioral symptoms.
5
Clinical research
Keywords: dementia; Alzheimer's disease; behavioral and psychological symptoms
of dementia; pharmacological treatment; nonpharmacological treatment
Author affiliations: Medical University of South Carolina, Department of
Psychiatry and Behavioral Sciences, Charleston, SC, USA
139
Address for correspondence: Dr J.E. Mintzer, Medical University of South Car-
olina, ARCP (Alzheimer’s Research and Clinical Programs), 5900 Core Road,
Suite 203, N Charleston, SC 29406-6076, USA
(e-mail: mintzerj@musc.edu)
Behavioral and psychological signs and
symptoms of dementia:a practicing 
psychiatrist’s viewpoint
Jacobo E.Mintzer,MD;Dario F.Mirski,MD;Kathleen S.Hoernig,MD
AEven though both syndromes have devastating conse-
quences for patients and their care providers, it is the
presence of behavioral symptoms and their impact on
care providers that ultimately precipitate the chain of
events that results in the demented patient’s placement
in a long-term care institution.
6This paper will focus on
the behavioral and psychological symptoms of demen-
tia.This focus was chosen because of the considerable
treatment challenge these symptoms present to clini-
cians and the burden they impose on patients, care
providers, and society.
Historical perspective
Although physicians have been aware of the presence
of behavioral symptoms in dementia since AD was first
described,
7 a definition of these symptoms was not
attempted until 1986.
8 In 1986, the syndrome defined
was agitation, ie, “inappropriate verbal and motor
behaviors that are not related to unmet needs or con-
fusion per se.”
9 Soon clinicians and researchers real-
ized that the problem was more complex than the
aforementioned and that patients presented not only
symptoms of agitation, but also symptoms of aggres-
sion, psychosis, alteration in circadian rhythm, depres-
sion, and more.
10 In 1996, the International Psy-
chogeriatric Association (IPA) called a consensus
conference to examine the available knowledge on
noncognitive symptoms of dementia. The goal of the
conference was to achieve consensus on the use of
more appropriate descriptive terms that would facili-
tate communication among researchers and therefore
foster further development of the field.The experts in
attendance agreed on an umbrella term that would
include all behavioral symptoms observed in the
dementia.The term was “Behavioral and Psychological
Symptoms of Dementia” (BPSD),
11 defined as “signs
and symptoms of disturbed perception, thought con-
tent, mood or behavior that frequently occur in
patients with dementia.”
12 As new treatment options
and scientific information emerged, another meeting
was called by the IPA.This meeting evaluated the new
data and concluded that a number of subsyndromes
could be identified within the BPSD umbrella. These
syndromes were psychosis, circadian rhythm (sleep-
wake) disturbance, depression, anxiety, agitation, and
other less well-defined syndromes. The following is a
brief summary of the current knowledge on BPSD with
suggestions as to how this information can be applied
to patient care.
Etiology
The etiology of BPSD is unknown. However, most
experts probably agree that the etiology of BPSD is
related to specific neuropathological brain lesions,
13 psy-
chological and environmental factors,or a combination
of both.
14The specific localization of these lesions in the
brain appears to be syndrome-dependent.
Neuropathological factors
Psychosis
As discussed previously, AD and other dementias are
brain disorders presenting with a broad range of neu-
ropathological lesions.When evaluating the etiology of
psychosis in BPSD in AD, for example, researchers
should not only establish the presence of neuropatho-
logical findings that explain the symptoms, but should
also evaluate whether these findings differ between AD
140
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Selected abbreviations and acronyms
AD Alzheimer’s disease
BEHAVE-AD Behavioral Pathology in Alzheimer’s Disease 
Rating Scale
BICU behavioral intensive care unit
BPRS Brief Psychiatric Rating Scale
BPSD behavioral and psychological symptoms of
dementia
CBT cognitive-behavioral therapy
CMAI Cohen-Mansfield Agitation Inventory
DAT depression of the Alzheimer’s type
EPS extrapyramidal symptoms
GAD generalized anxiety disorder
GBS Gottfries-Bräne-Steen dementia rating scale
NPI Neuropsychiatric Inventory
PHF paired helical filaments
RO reality orientation
SCU special care unit
TD tardive dyskinesia141
patients with and without psychosis and nondemented
psychotic patients.Fortunately,in recent years,a number
of investigators have reported neuropathological find-
ings that clearly differentiate the psychotic AD popula-
tion from both schizophrenic and nonpsychotic AD
patients. Specifically, AD patients with psychosis have
increased neurodegenerative changes in the cerebral
cortex, increased subcortical norepinephrine, reduced
cortical and subcortical serotonin, and abnormal levels
of paired helical filaments (PHF)–tau protein in entorhi-
nal and temporal cortices.
15
Circadian rhythm (sleep-wake) disturbance
It has been suggested that degeneration of the hypo-
thalamic suprachiasmatic nucleus (SCN),the “biological
clock” of the brain that imposes 24-hour rhythms in
physiology and behavior, plays a key role in disturbed
sleep-wake patterns.
16 Degeneration of suprachiasmatic
vasopressin cells has been demonstrated in postmortem
studies on brain tissue of AD patients.
17
Depression
Major depression in dementia of the Alzheimer’s type
(DAT) patients has been associated with increased
degeneration of brainstem aminergic nuclei,particularly
the locus ceruleus, and relative preservation of the
cholinergic nucleus basalis of Meynert. Associated
increases in the number of senile plaques or neurofi-
brillary tangles in the neocortex or allocortex have not
been found.
18 In addition,modest decreases in serotonin
and 5-hydroxyindoleacetic acid (5-HIAA) levels have
been found in AD patients.
Anxiety, agitation, 
and other BPSD syndromes
To the best of our knowledge, no specific relationship
has been established between anxiety, agitation, and
other BPSD syndromes and specific neuropathological
findings in AD or other dementias. AD and other
dementias, however, affect large areas of brain tissue
and cause deficits in a broad range of neurochemical
systems including gamma-aminobutyric acid (GABA),
dopamine, substance P, and others.
19 It is possible that
future research will reveal relationships between those
deficits and specific BPSD syndromes.
Psychological and environmental factors
To date,no clear relationships between most BPSD syn-
dromes and specific psychological and environmental
factors have been established.
20 However,Cohen-Mans-
field et al
8 have studied relationships between patient
needs,the environment,and agitation.Although a com-
plete review of the literature is beyond the scope of this
article a number of issues clearly emerge.The presence
of unmet medical needs is an important contributor to
all BPSD syndromes.For example,in an extensive nurs-
ing home study, Cohen-Mansfield and collaborators
found that a large number of patients with verbal
aggression had undiagnosed hip fractures.
9 Further-
more, an evaluation of the correlation between behav-
iors such as verbal aggression and environmental 
factors shows that the quality of the patient’s social
environment is inversely proportional to the presence
of verbal aggression.This suggests that an improvement
in social interactions can have a therapeutic effect on
verbal aggression.Indeed,a study by the same group of
researchers shows intervention based on increasing
social interaction to be better than a control interven-
tion in the treatment of verbal aggression.
8 Based on
the aforementioned example, we believe that behav-
ioral and environmental interventions should play a key
role in the management of BPSD, thereby challenging
clinicians and researchers to develop new and creative
interventions.
21
Conclusion
Although the etiology of BPSD remains unknown,avail-
able evidence suggests that a combination of behavior-
specific biological and environmental factors may be
partially responsible for the onset of BPSD.
Diagnosis
The diagnosis of BPSD is based on direct clinical history,
direct observation, psychiatric and physical examina-
tions,and reports by care providers.In addition,labora-
tory tests are used to evaluate the presence of medical
conditions that can trigger or exacerbate the clinical pre-
sentation of BPSD.
The clinical characteristics of BPSD are syndrome-spe-
cific.The following is a brief description of some of the
most commonly observed syndromes.
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The symptoms of psychosis are defined by the pres-
ence of hallucinations and delusions lasting for one or
more months. The onset of psychotic symptoms must
occur after the onset of the dementia in order to fit
this diagnosis. The main differential diagnosis is with
late-onset schizophrenia;however,symptom presenta-
tion of BPSD psychosis is substantially different from
schizophrenia. Symptoms such as misidentification of
caregivers and visual hallucinations are common in
BPSD psychosis and are rare in patients with schizo-
phrenia.In contrast,patients with schizophrenia usually
present Schneiderian first-rank symptoms,bizarre com-
plex delusions, and active suicidal ideation. These
symptoms are rarely observed in BPSD psychosis.Dis-
ease progression is also reported to be substantially
different in BPSD psychosis.Psychosis in schizophrenia
rarely shows remission,and the need for antipsychotic
treatment is prolonged; psychosis in BPSD has a
shorter duration and therefore requires shorter periods
of treatment.
Circadian rhythm (sleep-wake) 
disturbance in dementia
Circadian rhythm disturbances among BPSD patients,
termed sleep-wake rhythm disturbances for the pur-
posed of this paper,make caregiving extremely difficult
and are among the most important reasons for institu-
tionalization.The prevalence of sleep abnormalities in
demented populations may range from 20%-40%.
22,23
Circadian rhythms are important regulators of sleep in
humans. Sleep disturbances in patients with BPSD
have been strongly associated with other BPSD symp-
toms such as wandering, daytime agitation, and the
commonly described syndrome of increased agitation
in the late afternoon known as “sundowning.”
24 Sleep-
wake cycles among patients with BPSD have been
shown to degenerate and be replaced by arrhythmic
polyphasic patterns of sleep.
25 Additionally, nocturnal
sleep has been shown to be fragmented and associated
with a tenfold increase in daytime sleep.
26 The main
differential diagnosis is with other sleep disturbances
such as sleep apnea. Furthermore, the presence of
BPSD sleep disturbances can coexist with other sleep
problems, adding additional challenge to an already
complicated diagnosis.
Depression
To our knowledge, no specific definition for BPSD
depression is available.It is therefore recommended that
the clinician use available definitions of depression such
as those used in the Diagnostic and Statistical Manual of
Mental Disorders, 4th edition (DSM-IV) published by
the American Psychiatric Association.In addition,how-
ever, we recommend that some of the diagnostic con-
siderations described herein be followed.
Depressive symptoms in demented patients often fluc-
tuate and are particularly difficult to identify in patients
with advanced dementia because of language impair-
ment. Behavioral manifestations of depression (psy-
chomotor slowing,emotional lability,crying spells,insom-
nia, weight loss, alexithymia, and nihilism) can occur 
in demented patients without depression.
27 Depressed
patients with BPSD exhibit more self-pity,rejection sen-
sitivity,anhedonia,and fewer neurovegetative signs than
depressed older patients without dementia.
28 Research-
based depression rating scales for demented patients
have been developed to help discriminate between
depressed and nondepressed demented patients,
29,30 and,
while useful in research settings, widespread clinical
application has yet to be adopted.
The natural history of major depressive disorder in
BPSD patients is somewhat unclear.Most evidence sug-
gests that major depression tends to emerge during the
mild-to-moderate stage of cognitive impairment. Some
studies suggest that the emergence of major depression
in AD is associated with an increased mortality rate,but
no acceleration of cognitive decline.
31
Anxiety, agitation, and other BPSD syndromes
The presence of symptoms of anxiety in demented
patients has high-phase validity among clinicians.
Indeed, all currently available scales for BPSD include
an anxiety item. The Behavioral Pathology in
Alzheimer's Disease Rating Scale (BEHAVE-AD),for
example, includes four anxiety-related items: anxiety
regarding upcoming events,other anxieties,fear of being
alone, and other phobias. Although the Cohen-Mans-
field Agitation Inventory (CMAI) does not specifically
address anxiety symptoms, it presents two categories
that describe symptoms of anxiety. The categories are
nonaggressive physical behavior and nonaggressive ver-
bal behavior.The symptoms are pacing and aimless wan-
142
Clinical researchdering, constant request for attention, repetitive ques-
tions, trying to get to different places, complaining, and
general restlessness. Finally, anxiety is one of the ten
items evaluated for frequency and severity in the Neu-
ropsychiatric Inventory (NPI).
It is, however, surprising that, despite leading investi-
gators’ acknowledgment of the presence of anxiety
symptoms in dementia,no widely accepted qualitative
definition is available for generalized anxiety disor-
der (GAD), the most common anxiety disorder in
dementia. In the absence of other options, it is of
interest to observe that Chemerinski and associates,
using DSM-III-R GAD criteria managed to identify a
distinct group of demented anxious patients.
32
To date, there is no universally accepted definition of
agitation in BPSD. In the absence of such a definition,
we propose using the clinical approach advocated by
Cohen-Mansfield and collaborators.They view agitation
as a group of inappropriate verbal and motor behaviors
that are unrelated to the presence of unmet needs or
confusion per se.
8
Pharmacological treatment
As in previous sections the treatment of BPSD will be
reviewed syndrome by syndrome. Because to our
knowledge no specific syndromal approach is avail-
able for behavioral treatments, those will be jointly
reviewed.
Psychosis and aggression
In 1998, little information was available on the treat-
ment of psychosis and aggression in AD.An attempt to
bridge this gap in knowledge was made using an
expert consensus approach (A Special Report April
1998).
33 The resulting report, which included survey
results from approximately 80 experts,concluded that
risperidone was the first-line treatment for psychosis in
AD,followed by conventional antipsychotics.Extrapyra-
midal symptom (EPS) reactions and the long-term risk
of tardive dyskinesia (TD) are potential concerns with
conventional antipsychotics,especially at higher doses.
Indeed, the rate of extrapyramidal side effects is
reported to be as high as 20% in this population.
34 Fur-
ther, the annual incidence of TD with conventional
antipsychotic therapy is reported to be 25% in this
population.
35 If patients are unresponsive to first-line
therapy,the report recommended switching to another
atypical antipsychotic, high-potency neuroleptic, or
adding divalproex or trazodone.With regard to aggres-
sion, there was no majority agreement on first-line
treatment; however, valproex was cited as the most
popular of the treatment options. Divalproex was 
also suggested to be useful as an adjunct to antipsy-
chotics in psychotic patients who continue to be severely
aggressive (Expert Consensus Guideline Series,1998).
33
It is important to note this report was based on a sur-
vey completed in the two previous years,at which time
the use of donepezil was limited (donepezil was
launched in 1996). The major weakness in this infor-
mation is in its source. Recommendations were based
on a survey of experts rather than scientifically col-
lected data.
In recent years,scientifically collected data from large mul-
ticenter trials began to emerge for the treatment of BPSD,
especially psychosis. The first multicenter, randomized,
double-blind,placebo-controlled trial of BPSD psychosis
was recently published.
36The study evaluated the effects of
risperidone versus placebo in 612 demented patients.The
study revealed risperidone to be significantly better than
placebo in improving symptoms of psychosis and aggres-
sive behavior when used in 1-mg and 2-mg doses.
36A sim-
ilar randomized trial
37 of risperidone, placebo, and
haloperidol for BPSD demonstrated conventional neu-
roleptics to be modestly efficacious for treating aggres-
sion in demented patients, while risperidone was associ-
ated with a greater reduction in both the severity and
frequency of aggression than was either placebo or
haloperidol. The antipsychotic drug olanzapine was also
recently utilized in a randomized, double-blind, placebo-
controlled study with AD.This study included 206 patients.
This study found olanzapine 5 mg and 10 mg to be supe-
rior to placebo in the treatment of both psychosis and
aggression in BPSD patients.
38
Until recently, cholinesterase inhibitors were untested
in treating BPSD symptoms such as agitation,delusions,
and hallucinations. In a previous study, it was observed
that patients given tacrine at 120 mg a day or higher
were less likely to have entered a nursing home than
patients on lower doses.
39 It was hypothesized that this
decline was in part due to a decrease in the onset of
noncognitive symptoms in those patients.Furthermore,
in a study evaluating the effectiveness of physostigmine
slow release (SR),Thal et al
40 reported a decrease in the
onset of psychosis and aggression as well as other psy-
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chiatric pathology in the physostigmine SR–treated
groups. In addition, recent data on the cholinesterase
inhibitor donepezil indicate that this compound can also
improve behavioral symptoms commonly associated
with psychosis in AD,such as hallucination,apathy,and
aberrant motor behavior.
41 Furthermore, another large
multicenter trial using donepezil for AD treatment of
nursing home (NH) populations revealed a statistically
significant (P<0.05) difference (in favor of donepezil)
in the individual agitation/aggression response of the
NPI/NH assessment tool.
41 Similar findings with rivastig-
mine and galantamine (both cholinesterase inhibitors)
have recently been revealed.
42
The common limitation of all these studies is that 65%
or fewer of the patients were considered responders
either for psychosis or aggression at doses with a benign
side-effect profile.
36,43 Recently, researchers have specu-
lated on the possible benefits of combining more than
one treatment approach,
37 and future research will prob-
ably guide us on the use of these types of treatments.
Circadian rhythm (sleep-wake) disturbance in BPSD
Standard pharmacological treatment with benzodi-
azepine and antipsychotic medications has limited or
even adverse effects in demented elderly people,includ-
ing excessive sedation, confusion, impaired cognition,
and personality changes.
44 Nonpharmacological treat-
ments such as bright light therapy have been studied
with varying results.
45-48
Anxiety, agitation, and other BPSD syndromes
Only one report of a multicenter pharmacological clini-
cal trial specifically addressing the response of anxiety
symptoms in AD patients to treatment is available.The
study presented by Street and associates (1999),reports
on the response of anxiety symptoms in AD to olanzap-
ine.In this study of 206 subjects treated in double-blind
fashion with either placebo or olanzapine 5 mg, 10 mg,
or 15 mg, the authors report a statistically significant
reduction in the anxiety symptoms of the NPI in
demented patients treated in the 5-mg group. Further-
more,a statistically significant symptom reduction over
placebo was observed using the anxiety/depression items
of the Brief Psychiatric Rating Scale (BPRS) (somatic
concerns,anxiety,guilt feelings,and depressive mood) in
the 5-mg and 10-mg olanzapine treatment groups.
It is of interest to observe the response of anxiety symp-
toms in another study evaluating treatment response of
demented patients with BPSD.
36 In this study,the inves-
tigators evaluated 612 demented patients presenting
with psychosis,aggression,and a variety of other symp-
toms of BPSD. Patients were treated with risperidone
0.5 mg, 1 mg, 2 mg, or placebo. Although patients did
not show response in the anxiety items of the BEHAVE-
AD,they did show statistically significant improvement
over placebo in the 1-mg and 2-mg patient groups on
both anxiety-related items (see above) in the CMAI.
Finally, Gottfries and associates (1992) evaluated the
response to citalopram given at doses of 10 to 30 mg 
a day in 98 patients suffering from dementia and
depression (see reference 18).They reported statistically
significant differences with placebo in the anxiety items in
demented patients as measured by the anxiety items of
the Gottfries-Brane-Steen global dementia rating Scale
(GBS).These changes are reported to occur at 4 weeks.
To date, no report has addressed the issue of agitation 
in demented patients per se, although all previously
reported studies find improvement in agitation as mea-
sured by the different rating scales. One recent report
suggests that mood stabilizers can be of value in the
management of agitation per se in the dementia popu-
lation. The following is a brief review of the available
literature on this subject.
Carbamazepine has been considered as a possible treat-
ment for agitation in demented patients based on
reports that it reduces impulsive behavior in other dis-
orders.
49 Following initial reports, there have been four
case reports
44,50-52 three open-label studies,
53-55 and two
double-blind, placebo-controlled, crossover studies,
56,57
all of which reported moderate improvement in a wide
range of agitated behaviors. One of the most recent
studies was conducted by Tariot and colleagues.
57 Using
a nonrandomized,placebo-controlled,crossover design
in 25 agitated patients, carbamazepine and placebo
were administered during two 5-week periods, sepa-
rated by a 2-week washout period.The carbamazepine
dose was determined by a nonblinded physician (modal
dose was 300 mg/day).This study included 25 subjects,
and outcome measures showed significant decrease in
overall agitation as determined by the BPRS (P=0.03)
as well as in measures of global improvement
(P=0.001).The authors concluded that carbamazepine
could be a useful tool for the treatment of agitation in
this patient population.145
Valproic acid could also be useful in these patients, as
described in the literature,
58,59 although large-scale dou-
ble-blind studies are lacking. Side effects from mood sta-
bilizers,such as sedation,confusion,and ataxia,should be
clinically monitored. Routine laboratory tests should be
performed during treatment with carbamazepine (eg,
blood cell count for bone marrow suppression,electrolytes
for hyponatremia, drug levels for toxicity) and valproic
acid (eg,liver function tests for hepatotoxicity,drug levels
for toxicity) in demented patients with agitation.
The use of lithium carbonate in the elderly is limited due
to the risks of inducing delirium,
60 particularly in the med-
ically compromised patient. Schneider et al
61 found that
lithium carbonate was effective only in one in six patients
with AD and aggressive behavior. The literature sug-
gests
62,63 that lithium can be considered in cases where
aggressive behavior is related to mood instability.
Nonpharmacological interventions
Historically,older adults have not been considered good
candidates for nonpharmacological, psychotherapeutic
interventions.
64 However, an increasing number of
researchers have studied the psychosocial issues con-
fronting aging adults, and their response to individual
and group therapies.
65
Literature reviews relating to specific psychotherapeutic
interventions with elderly patients are available and
include the behavioral assessment and treatment of anx-
iety, reduction in insomnia, behavioral management of
dementia, the use of reminiscence therapy, and group
family caregiver interventions.
66-69
A detailed literature review of BPSD patients demon-
strated that most studies are of a pharmacological type
and that there are few systematic studies of behavioral
or environmental interventions.
70,71 The existing studies
rarely specify a syndrome.These studies often relate to
specific behaviors, such as wandering, or to treatments
recommended for a given stage of dementia. For this
reason,in this section we will depart from the previously
used syndromal model and review nonpharmacological
interventions as a group.
Nonpharmacological interventions should be consid-
ered the foundation of treating behavioral symptoms in
persons with BPSD.Because the progression and impact
of BPSD vary from person to person, it is critical that
interventions be explored, designed, implemented, and
assessed on an individual basis. It is important also to
consider that a number of interventions can be utilized
with one individual and that many of the interventions
are beneficial to family and professional caregivers, as
well as the person with BPSD (for example,music ther-
apy, relaxation techniques, etc). It should be noted that
these interventions may also be very beneficial to per-
sons who have dementia and do not exhibit BPSD
symptoms.In discussing nonpharmacological approach-
es,particular emphasis will be placed on family support
and education,behavioral interventions,environmental
considerations,special care units,and professional care-
giver stress.
Family support and education
Family caregivers of persons with dementia have been the
focus of extensive research. Studies have consistently
demonstrated that caregiving is stressful and can result in
increased psychological and physical distress.
72,73 Family
caregivers often prefer avoiding or delaying the place-
ment of elderly members in a long-term care facility, and
spouses of caregivers are even more reluctant to do so
than other relatives.
74 Literature reviews by Zarit and Teri
have summarized the research on various psychoeduca-
tional,psychotherapeutic,and self-help interventions that
have been used with persons caring for an older adult.
75
There is evidence that brief individual or group treat-
ment with professional therapists can lead to reductions
in self-reports of caregiver distress. Greene and Mona-
han recruited family caregivers living in the community
whose levels of stress placed their elderly care recipi-
ent at risk for being institutionalized.
76 Significant reduc-
tions in caregiver anxiety, depression, and burden were
observed following 8 weeks of group counseling that
contained educational and relaxation components.
Another family caregiver study demonstrated that nurs-
ing home placement could be delayed significantly when
a long-term family intervention program was utilized.
77
However, a number of caregiver studies have not col-
lected follow-up data, and, when this information is
available, there are inconsistent findings, especially in
terms of maintaining improvement in psychological
functioning over a period of time.
Support groups for caregivers of persons with dementia
are available throughout the world.Again,while there are
many anecdotal observations on the benefits caregivers
receive from sharing experiences and information with
their peers,there has been little empirical research to date.
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ventions that have not been thoroughly examined and
researched. For some time, professionals working with
families have observed the benefit that respite care pro-
vides. Respite care enables a family member to have
“time-off” from their caregiving responsibilities and
comes in a variety of forms. Assistance with personal
care by a home health aide, a volunteer sitter, or the
opportunity to take a care recipient to an adult day pro-
gram are examples of respite care. Unfortunately, there
have been few empirical studies or outcome measure
initiatives developed to research the efficacy of respite
care services.
77
Behavioral interventions
The appropriate utilization of interventions in individu-
als with BPSD depends on a number of variables,includ-
ing where the person is in the progression of the disease.
For example, in the early stage, common symptoms
include depression,anxiety,and loss of self-esteem.Rec-
ommended treatment could be psychotherapy, partici-
pation in an early-stage dementia support group, and
reality orientation.In middle-stage dementia,behavioral
problems often occur and the family begins to seek assis-
tance through services such as home care and adult day
care.Psychotherapy is usually not an effective interven-
tion in an individual with dementia at this stage because
it is dependent on memory retention and insight.Instead,
validation therapy may provide an appropriate approach
to middle stage when the patient has BPSD.
In the later stages of dementia, the person becomes
extremely dependent, requiring a high level of assis-
tance with toileting and personal hygiene. Therapeutic
touch and the use of soothing music may provide the
reassurance needed to avoid a catastrophic reaction.It is
during this stage that most families look to long-term
care facilities for providing appropriate care.There is a
growing interest in the use of psychosocial interventions
to help ease some of the adjustment problems associated
with long-term residential care. Common interventions
include reality orientation and validation therapy.
Psychotherapy
The vast majority of controlled, experimental outcome
studies on psychotherapy with aging adults fall into one of
two broad categories:(i) psychoeducational;or (ii) cogni-
tive-behavior therapy (CBT). Psychoeducational thera-
pies emphasize psychological theories and techniques.In
contrast, CBT is an approach that combines the concep-
tual and applied work of various cognitive and behavioral
learning models.CBT has been researched with geriatric
outpatients and inpatients, medically stable and unstable
older adults,and in group and individual intervention set-
tings with aging adults.There is also a small but increasing
amount of research literature suggesting that CBT is an
effective treatment for depression in elderly patients.
78-82
These interventions emphasize cognitive training,sensory
stimulation, and physical rehabilitation, rather than
improvements in social functioning.
Reality orientation
Reality orientation (RO) was developed in the United
States in the 1960s. It is a basic technique used to reha-
bilitate persons having some form of memory loss,con-
fusion,and disorientation in time,place,and person.RO
has two formats:24-hour RO and classroom RO.Class-
room RO is an intensive cognitive retraining program
conducted for about 30 minutes each day; 24-hour RO
involves active orientation information cueing by all
staff at every opportunity. RO, however, is beneficial
only as long as the resident has the capacity to retain
current information.Persons in the middle to late stage
of dementia will not benefit from RO, and in some
instances can become frustrated and agitated when
asked RO-type of questions.
Validation therapy
Validation therapy was developed by Naomi Feil in
1982. It is an individual and group intervention that
focuses on the emotional content of what someone is
saying versus the factual content.The therapist validates
what someone is saying by acknowledging the emo-
tion(s) being expressed by the person (also referred to
as “subjective reality”). This type of therapy has been
observed to work especially well with memory-impaired
persons such as those with dementia.
83
Reminiscence and life review
Up until the 1960s, reminiscing by older adults was not
considered a healthy sign of aging. In 1961, however,
Butler formulated the concept that reviewing one’s life
Clinical research
146may be a positive form of placing experiences in proper
perspective and working through unresolved conflicts.
84
Empirical trials have been conducted using reminiscence
and life review to reduce depression and anxiety and to
increase feelings of self-esteem and life satisfaction in
the elderly.Although results have been promising,find-
ings have been inconsistent.
85 A number of variables
may contribute to these differing impact rates such as
the frequency and duration of the intervention, patient
age, the setting (ie, a private residence or a long-term
care facility),what measures of change are being used to
assess treatment outcomes, whether the format is for
individual or group therapy, and the use of other exter-
nal stimuli such as music.
86-91
Reminiscence therapy has become a popular form of
treatment in individuals with dementia because it
depends more on personal experience than a factual
recall of events.
92,93Also,reminiscence can help patients
come to terms with their situation,especially in the early
stages of the disease when long-term memory of distant
events is relatively preserved compared to short-term
memory or the ability to recall recent events. Reminis-
cence or life review focuses on something the patient
can still do and helps to maintain a sense of identity.
The evidence for the effectiveness of reminiscence in
individuals with dementia is generally positive. One
study of 27 nursing home residents with dementia indi-
cated that the self-reported level of depression in remi-
niscence group participants was positively affected com-
pared with participants in the supportive therapy and
control groups. While there were no significant effects
found for cognitive or behavioral functioning,the study
results indicated the applicability of reminiscence ther-
apy with persons with dementia.
94
Therapeutic activities and creative arts therapies
Therapeutic activities and the creative arts therapies
have been recognized as beneficial, especially in per-
sons with dementia living in long-term care facilities.
Therapeutic programming emphasizes a balance of
group and individual activities that promote strengths,
personal interests, and abilities, as well as accomplish-
ments,and the opportunity for self-expression.Creative
arts therapies include music, art, dance/movement,
drama,and bibliotherapy (literature and poetry).
A creative arts therapy is the controlled use of an art
medium in the treatment,rehabilitation,education,and
training of persons with physical,mental,and emotional
disorders. For example, music has been recognized as a
therapeutic tool with documented psychological and
physiological effects for persons with dementia.
95 Cohen-
Mansfield et al reported reduced screaming in a study of
nursing home residents where music was a part of the
environment.
96 Knopman and Sawyer-DeMaris found
that music is usually preferred and enjoyed by patients
with dementia in contrast to background noise from a
television.
97 (See section on Environment.) 
Music interventions can be used in conjunction with
exercise, as well as reminiscence and RO. Because peo-
ple naturally move rhythmically,tap their feet,and clap
their hands “in time” to the music, this medium can be
used to increase movement in patients with limited
range of motion. However, in attempting to find the
appropriate balance of stimuli for the persons with
dementia, it is critical that the type of music and vol-
ume level be selected carefully.
Therapeutic touch
An ancient intervention that has recently gained popu-
larity in the field of health care is the use of therapeutic
touch.In a survey of nursing home management of dis-
ruptive behavior, 38% of staff listed touch as an inter-
vention.
98 While few empirical data exist, a number of
long-term care settings that offer professional massage
therapy and whirlpool treatments indicate how benefi-
cial this service has become. The use of touch with
infants and autistic children has been documented;how-
ever, empirical studies of this intervention with the
elderly are needed.
The environment
The term “environment”is used here in the most global
sense to encompass everything from physical modifica-
tions to staff attitudes,approaches,and demeanor.This is
commonly referred to as the therapeutic “milieu.” A
therapeutic milieu considers “problem behaviors” as
meaningful expressions representing unmet needs and
responds to these needs by using supportive interven-
tions. A central element that can determine the effec-
tiveness of a therapeutic milieu is the quality of all inter-
actions that take place within the setting.This includes
interpersonal interactions as well as individual actions
and reactions to one’s surroundings.
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the potential to be used as a therapeutic tool.Gunder-
son formulated a model that provides a “blueprint” of
the therapeutic processes in psychiatric milieus.
99 The
model describes five elements that effect the thera-
peutic environment:safety,structure,support,involve-
ment, and validation.
The environment also can be a source of intense frus-
tration and insecurity, especially for patients with AD.
The environment plays a significant role as an individ-
ual’s level of impairment increases.There is no “perfect
environment”for dementia sufferers,but two key factors
that are responsible for an effective environment are
creativity and flexibility. There is a growing amount of
literature on design elements for individuals with
dementia. However, given the individuality of the dis-
ease and its progression, there exists little empirical
research and few protocols on which design practices
work best under what circumstances.
Behavioral environmental approaches
Individuals with AD can have symptoms that may
include paranoia,depression,and severe agitated behav-
iors such as hitting,kicking,screaming,and self-injury.
100
These additional manifestations are often major risk
factors for caregiver distress and nursing home place-
ment.
101 An alternative approach to the treatment of
individuals with dementia who have severely agitated
behavior is the use of behavioral environmental tech-
niques,implemented in conjunction with,or in place of,
traditional pharmacological treatments.
102
A behavioral environmental approach involves careful
assessment of the current living environment and the
behavior of the patients with dementia. This involves
analyzing the behavior of persons that he or she inter-
acts with on a fairly regular basis, such as family mem-
bers, paid caregivers, and friends. For example, a home
environment with a high level of stimulation (ie, televi-
sion,radio,lights,furniture,pets,etc) can cause increased
agitation in a person with dementia. Additionally, an
untrained caregiver could provoke a catastrophic reac-
tion from the person with dementia by demanding a
level of performance that is not possible due to the
dementing process. A behavioral environmental
approach would be to eliminate or decrease the amount
of unnecessary stimulation, such as background noise,
and provide caregiver training on the limitations of the
disease, as well as specific approaches to maximize the
care recipient’s level of functioning.
Behavioral intensive care units 
Intensive care units were developed in the late 1950s
and early 1960s in response to the perceived need for an
increased level of observation and recording of critically
ill medical and surgical patients.
103 This model of care
demonstrated that a person in an environment where
variables are closely monitored,and prompt treatment is
designed and implemented, had a significant improve-
ment in survival rate and quality of life.
104
Behavioral intensive care units (BICUs) are designed
on the model described above, and therefore assume
that agitated behaviors, especially in persons with
dementia,are not random acts.Instead,this behavior is
determined by either undetected medical problems
(such as asymptomatic urinary tract infections or pneu-
monia) or elements in the environment that trigger,sus-
tain,or extinguish the observed behavior.The elements
of triggering,sustaining,or extinguishing agitated behav-
iors vary from individual to individual as well as from
behavior to behavior.
105
The BICU strategy calls for intensive behavioral map-
ping and treatment.The treatment consists of two steps:
(i) design and implementation of therapeutic interven-
tions;and (ii) modification of the environment to which
the person will return, including caregiver training.
The therapeutic interventions are designed to achieve
two goals: (i) modify the stimuli that cause the agitated
behavior (environmental, medical, and/or psychiatric),
and (ii) if the stimuli causing the behavior cannot be
extinguished,then the social and physical environment is
modified in such a way that the targeted behavior can be
accepted.
BICU goals are achieved by placing the person with the
agitated behavior(s) in a short-term unit where a thor-
ough medical, psychiatric, and functional assessment is
conducted.The agitated behavior(s) is specifically iden-
tified and evaluated.An individualized treatment plan is
designed, implemented, and continually assessed. Dis-
charge planning should begin at the time of admission
and the return environment be assessed and modified as
necessary. Family/caregiver education, training, and
counseling should be provided. Follow-up visits to the
home after discharge can be well suited to evaluating
the effectiveness of the BICU interventions.
102
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As the 1990 Nursing Home Reform Act states: “The
resident has the right to be free from any physical
restraints imposed for the purpose of discipline or con-
venience and not required to treat the resident’s med-
ical symptoms.”
106
The use of physical restraints in nursing homes has long
been debated among staff, physicians, administrators,
and advocates for the elderly.
107 Even before the Fed-
eral regulations were enacted in 1990,there was a grass-
roots movement exploring the use of such restraints.The
Kendal Corporation, a nonprofit entity that manages
several nursing homes, had successfully operated these
facilities as restraint-free environments for many years.
In 1991, Kendal initiated “Untie the Elderly,” a project
to increase awareness and educate others throughout
the country on how to become a restraint-free facility.
Traditionally, the rationale for using physical restraints
includes the concern for safety risks such as falls, the
need to prevent self-injury,legal liability issues,and try-
ing to compensate for inadequate or untrained staff.
However, there are no scientific data to suggest that
restraints prevent falls.
108 Conversely, in facilities where
restraint use has been decreased or eliminated,the inci-
dence of injuries from falls has decreased.
109
Few people are aware of the adverse and even harmful
effects of physical restraint.The physiological effects of
simple immobility caused by restraints have been well
characterized.
110,111 Immobility causes decreased muscle
mass, which results in weakness, loss of balance, and,
along with bone demineralization, increases the risk of
falls and fractures.Additionally,the metabolic rate slows,
and circulatory responses can include decreased cardiac
output, increased risk of blood clots, and orthostatic
hypotension. Any of these conditions can create a
decreased breathing volume, which can result in pneu-
monia,a leading cause of death in the elderly.Common
side effects of immobility include constipation,increased
skin breakdown and infections,and increased confusion.
There have been no successful legal claims against long-
term care facilities based solely on the failure to restrain
a resident.
112 Additionally, it is believed that the move-
ment of Federal regulations towards the least-restric-
tive environment possible will impact future liability
claims. Finally, it is unrealistic to believe that it takes
less time to supervise and protect a resident in restraint.
Studies by Blakeslee et al have determined that resi-
dents in restraints actually take an estimated 4.58 hours
per day of personal attention to comply with restraint
standards of care, compared with 2.7 hours per day of
personal attention needed when the restraints were
removed.
109
The initial step to changing the use of restraints must
involve all levels of staff, including physicians, adminis-
trators, and nonnursing staff. Written guidelines should
clearly state the facility’s policy and these should be
shared with all staff,family members,volunteers,visitors,
funding sources, and regulators.A second step involves
education and replacing myths with accurate informa-
tion.The final step is identifying alternative options for
managing and accepting the resident’s behavior.There is
no one “right” answer, but staff should be encouraged
to develop,implement,and assess innovative approaches.
Alternatives to physical restraints often fit into one of
four categories:medical treatment,environmental mod-
ifications, behavioral interventions, and rehabilitative
measures.
113
Special care units
The Office of Technology defines these as specially
designed environments with skilled staff to provide
ongoing care and programs addressing the special needs
of patients with Alzheimer’s disease. There has been a
growing trend for nursing homes to offer specialized
programming for residents with dementia.Termed “spe-
cial care units”(SCUs),these programs vary enormously
from specifically designed freestanding facilities with
highly trained staff to institutions that simply have one
wing that segregates residents with dementia from the
physically frail.
The first SCU opened in 1974 at the Philadelphia Geri-
atric Center. In 1992, at least 10% of all nursing homes
indicated that their facility offered an SCU. Approxi-
mately 15% to 25% of these same facilities reported
that they charged a higher rate for the SCU. In 1994,
there were over 1500 SCUs in the US caring for about
50 000 residents. It is projected that these numbers will
increase geometrically in the near future.
114
An SCU should exemplify the most current state-of-the
art environment. This involves utilizing the nonpharma-
cological interventions previously described. However, a
1994 study conducted by the Alzheimer’s Association and
the University of Iowa produced some unsettling infor-
mation.
115 The study involved the extensive interviewing of
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nursing home licensing agencies from 29 states, and 453
family members who have or had a family member in a
special care unit.The major findings were:
• The professional advocates reported little difference
between SCUs and traditional nursing homes. While
there were few serious problems, a majority of these
professionals said that most of the SCUs were no bet-
ter than other nursing homes in the very features that
should distinguish “special care,”ie,specialized activi-
ties, sufficiently trained staff, the absence of involun-
tary seclusion of residents, and the ability to manage
challenging behaviors.
• One third of the families said they paid more for SCUs
and one third said they did not know if they were pay-
ing more.This is problematic,especially if there is little
or no difference in the care provided by these units.
• Nearly all family members reported satisfaction with staff
attitudes and safety precautions and the majority would
place their family member in the same SCU again.
• A majority of the professional advocates favored the
creation of rules governing the operation and evalua-
tion of SCUs.
114
Individuals with dementia need additional consideration
with regard to staffing,environmental considerations,level
of stimuli, and safety. Traditionally, nursing homes were
often unable to meet these special needs adequately,hence
the development of SCUs. However, a number of issues
surrounding SCUs need further exploration and resolu-
tion. Some professionals believe that the benefits from
clustering persons with dementia in separate areas are
outweighed by the stigma of segregation,the lack of higher
functioning persons as role models, and the absence of
established protocols for dementia care. Additionally, a
number of these units lack specific admission and dis-
charge criteria, thus reinforcing the belief held by some
that SCUs are simply “repackaging” traditional nursing
home care for AD families. The National Institute on
Aging has been conducting a nationwide longitudinal
study of SCUs for several years. However, preliminary
data have been inconclusive regarding the efficacy and
cost-effectiveness of these programs.
Professional caregiver stress
The psychological stress of caregiving has been well doc-
umented. A review by Schultz et al thoroughly evalu-
ated the existing empirical literature that described the
prolonged consequences of caregiving.
73 The adverse
mental health consequences were frequent,particularly
the development of depression,anxiety,and hostility or
anger.There also exists a significant amount of research
on stress or “burnout”in people in various helping pro-
fessions, including nursing home staff and staff caring
for persons with dementia.
116-121
Stress is the combination of the body’s physical, mental,
and chemical responses to demands. Occupational stress
has been defined as the psychological or physical discom-
fort associated with work that is characterized by heavy
demands and limited control over working conditions.
112
Nursing home employees have been found to be at sig-
nificant risk for high levels of occupational stress. Con-
tributing factors include the physical and emotional
demands of the work, the negative perception of long-
term care is reinforced by low wages,and few options for
career advancement and/or recognition. Consequences
of this stress include the adverse mental health states
previously mentioned as well a loss of self-esteem, loss
of mastery or control over work situations,and increased
absenteeism,lateness,utilization of sick leave and health
benefits, and staff turnover. In addition, stressed care-
givers may stereotype the elderly.
122 This can lead to
diminished expectations about the nursing home resi-
dent, and the transference of this belief onto the resi-
dent.
123 Stressed caregiver behaviors also include child-
like treatment of residents,indiscriminate restraint use,
and physical and verbal abuse.
117
Self-care interventions
Learning ways to reduce and handle chronic stress
requires a change in lifestyle.Stress reduction techniques
can range from very simple to highly specialized biobe-
havioral treatment. A holistic approach to reducing
stress should include learning new coping skills,such as
the ability to set limits,problem solving,and the practice
of positive thinking.The overall goal should be a healthy
lifestyle that combines self-care interventions as well as
opportunities for education, support, and a responsive
work environment.
One popular stress-relieving technique is known as the
relaxation response.This response produces a relaxed state
with reduced breathing and heart rate.A relaxed state is
accomplished by sitting quietly, closing one’s eyes, while
relaxing muscles progressively from the feet to the head
Clinical research
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124 Other similar
interventions include imagery techniques such as visual-
ization, guided imagery, active remembering, meditation,
chanting,channeling,and listening to calming music.
A healthy lifestyle includes a balanced diet,regular exer-
cise,and adequate rest.A nutritionally sound diet should
limit alcohol, caffeine, and sugar intake. Also to be
avoided are skipped and hurried meals, as well as
chronic dieting. Exercise has been found to be a stress
reliever. Exercise releases endorphins into the blood
stream,which naturally assist the body to relieve stress.
125
Staff training and support
Personal and professional caregivers need to continually
update and enhance their knowledge. Long-term care
facilities should provide staff with ongoing education,
training,and support.Moos and Schaefer found that occu-
pational stress can be impacted by the level of social sup-
port staff perceived from their coworkers and supervi-
sors.
126A growing number of long-term care facilities offer
support groups for employees. The purpose of these
groups is to provide opportunities for expressing feelings,
sharing information, and gaining new insight and under-
standing.Additionally,the utilization of resident-centered
strategies with a multidisciplinary team approach can be
effective in resolving stressful caregiving situations.Inclu-
sion of the resident and the family,whenever possible,can
further the establishment of realistic expectations and the
opportunities to view the resident as a unique individual
and not as a “behavior problem.”
123
Workplace environment
Productivity studies have traditionally recognized the
effects of physical features such as lighting, noise, and
workstation features on efficiency and accident rates.
However, research on stress in the helping professions
has primarily focused on relationships within the work
group and between management and employees. The
effect of the physical environment has only recently
begun to be explored.
One recent study looked at twelve AD adult day care
centers and the impact of the workplace environment on
staff.
127 The results of the study found that work stress
can be managed in the AD care setting if the demands of
working with a cognitively impaired population can be
minimized and staff member,have some degree of con-
trol over their environment. Staff members identified
four specific aspects of the workplace environment that
impacted occupational stress:space and spatial arrange-
ments,security and wandering features,bathrooms/per-
sonal care space, and staff space/ privacy.The following
recommendations are based on the authors’ own expe-
rience in providing AD care and confirmed in the find-
ings from the study conducted by Lyman et al.
127
Space considerations should include the avoidance of
congestion,especially in transitional areas such as halls,
reception areas, and in front of rest rooms.Traffic flow
can be hampered when it is unclear to participants how
to get from one area to the next. Staff members may
have to spend inordinate amounts of time simply mov-
ing patients from one area to the next.It is also impor-
tant to have smaller rooms as well as group activity
space.Extremely large open spaces such as “day rooms”
can be overwhelming for the cognitively impaired,and
are difficult to control in terms of noise level and pri-
vacy.An ever-present concern in providing  care in AD
is the safety of potential wanderers. In facilities where
security systems are inadequate,much of the workday is
dominated by the anxiety produced by the fear that res-
idents may become lost or leave the facility unattended.
When rest rooms are inconveniently located, it can
require one-on-one staffing in order to adequately meet
residents’ personal needs.residents who might indepen-
dently find and use the bathroom may become unnec-
essarily dependent when personal care facilities are
poorly designed and located.
Inadequate space is often problematic in facilities.This
includes space for storage,personal belongings,and pri-
vacy.The work becomes stressful when there is no pro-
vision for a staff area with some degree of visual and
acoustic privacy. As one staff member said, “A break
really isn’t a break when there is no place to get away for
awhile.”Also, it is difficult to properly support employ-
ees when there is no private space for supervisory dis-
cussions, and other work-related conversations that
require confidentiality and privacy.
Other environmental considerations should include out-
door space for staff and residents.Also,way-finding cues
such as brightly colored bathroom doors, and defined
wandering paths offer greater independence for con-
fused persons and,in turn,reduce demands on staff.Fur-
thermore, when staff are involved in environmental
modifications there is an increased sense of control over
working conditions. ❑
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Signos y síntomas conductuales y 
psicológicos de la demencia: un punto
de vista del psiquiatra clínico
La Enfermedad de Alzheimer se presenta típicamente
como dos síndromes que se sobreponen, uno cognitivo y
otro conductual. El síndrome conductual se caracteriza
por psicosis, agresividad, depresión, ansiedad, agitación y
otros síntomas frecuentes, -pero no bien definidos- que se
agrupan bajo la denominación genérica de “síntomas con-
ductuales y psicológicos de la demencia” (SCPD). Este
síndrome se divide a su vez en varios subsíndromes: psi-
cosis, trastornos del ritmo circadiano (sueño-vigilia),
depresión, ansiedad y agitación. Son los SCPD los que
afectan a los cuidadores de estos pacientes y en definitiva
los que precipitan la cadena de acontecimientos que llevan
muchas veces a tener que hospitalizar al paciente en algu-
na institución por tiempo prolongado. El desafío terapéu-
tico consiste en eliminar las posibles causas médicas ocul-
tas (fractura de cadera no diagnosticada, infección urina-
ria asintomática o una neumonía). Las intervenciones far-
macológicas incluyen la risperidona y -cada vez con
mayor frecuencia- los inhibidores de la colinesterasa para
el control de la psicosis (aunque la frecuencia de respues-
ta favorable es de sólo un 65% con dosis tolerables);olan-
zapina, risperidona y citalopram para la ansiedad y, car-
bamazepina y ácido valproico para la agitación. Sin
embargo, existen evidencias crecientes a favor de interven-
ciones no farmacológicas,las que podrían llegar a ser con-
sideradas como la base del tratamiento de los SCPD. Los
trastornos de conducta pueden ser enfocados como res-
puestas significativas a necesidades insatisfechas en el
medio terapéutico. Ya que la progresión e impacto de los
SCPD varían entre los pacientes, las intervenciones deben
ser exploradas, diseñadas, implementadas y evaluadas en
forma individual. Estas intervenciones incluyen soporte y
educación familiar, psicoterapia, orientación a la realidad,
terapia de validación,recuerdos y revisión de la vida,inter-
venciones conductuales,actividades terapéuticas y terapias
artísticas creativas,consideraciones ambientales (incluyen-
do espacios de libre desplazamiento), unidades de cuida-
dos intensivos conductuales y, diseño de lugares de traba-
jo y prácticas que ayuden a los cuidadores profesionales al
manejo continuo del estrés.
Les signes et symptômes psychologiques
et comportementaux de la démence : 
le point de vue du psychiatre
La maladie d’Alzheimer se manifeste typiquement par
deux syndromes fréquemment imbriqués, l’un cognitif,
l’autre comportemental. Le syndrome comportemental
associe psychose, agressivité, dépression, anxiété, agitation
ainsi que d’autres symptômes fréquents quoique moins
bien définis.L’ensemble de ces manifestations est regroupé
sous l’entité générale “symptômes comportementaux et
psychologiques de démence” (SCPD), elle-même divisée
en plusieurs sous-syndromes : psychose, troubles du ryth-
me circadien (veille-sommeil), dépression, anxiété et agita-
tion. C’est le SCPD, avec son retentissement sur les per-
sonnes prenant en charge ces patients, qui précipite la suc-
cession des événements aboutissant à l’hospitalisation en
long séjour.Toute la difficulté thérapeutique consiste à trai-
ter les situations restées sans médicalisation,telles une frac-
ture de hanche non diagnostiquée ou une infection urinai-
re ou une pneumonie asymptomatiques). Le traitement
pharmacologique de la psychose repose sur la rispéridone
et, de plus en plus, sur les inhibiteurs de la cholinestérase
(mais avec un taux de réponses de 65 % seulement aux
doses tolérées),tandis que l’anxiété est traitée par l’olanza-
pine, la rispéridone et le citalopram, et l’agitation par la
carbamazépine et l’acide valproïque. Néanmoins, de plus
en plus d’arguments militent en faveur de l’approche non
pharmacologique,au point que celle-ci doit désormais être
considérée comme le traitement de fond du SCPD. Les
troubles du comportement sont considérés comme des
réponses significatives à des besoins insatisfaits par la prise
en charge thérapeutique.Comme l’évolution et l’impact du
SCPD varient selon les patients,les mesures à prendre doi-
vent être examinées, choisies, appliquées et évaluées de
façon individuelle.Celles-ci comprennent :le soutien fami-
lial et l’éducation, la psychothérapie, l’orientation par rap-
port à la réalité,la thérapie par validation,l’évocation de la
vie antérieure et des réminiscences,les thérapies comporte-
mentales, les activités thérapeutiques et l’art-thérapie,
l’aménagement de l’environnement (y compris des équipe-
ments qui ne doivent plus recourir aux entraves phy-
siques), le développement d’unités de soins intensifs du
comportement, et l’adaptation du lieu de travail, sans
oublier les mesures visant à faciliter la prise en charge
continue du stress des professionnels de santé.
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